Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer

Remziye Zaim*, W. Ken Redekop, Carin A. Uyl-de Groot

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Scopus)
19 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Biochemistry, Genetics and Molecular Biology

Economics, Econometrics and Finance

Neuroscience